Healthcare & Medical Devices Global On demand · 24-48h

Global Blood Analyser Market Strategic Research Report

Global Blood Analyser Market Strategic Research Report
$3,500 USD
Market Research Reports
Strategic Research Report
Global Blood Analyser Market
$1.32B2025
4.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Three-part Differential, Five-part Differential

By Application: Clinical, Screening, Research, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Sysmex Corporation, Danaher, Abbott Laboratories, Siemens Healthineers, HORIBA, Boule Diagnostics AB, Nihon Kohden, BioSystems, Diatron, Mindray Medical, DYMIND, Urit Medical, Zybio, Dirui Medical, Maccura, Sinnowa

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 143 pages
Market size 2025
$1.32B
Billion USD
Forecast CAGR
4.4%
2025-2032
Forecast 2032
$1.8B
Projected
Regions
5
Asia Pacific · Latin America · MEA · Europe · North America

نظرة عامة

Scope of the Report

The global Blood Analyser market size is predicted to grow from US$ 1,320 million in 2025 to US$ 1,788 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.

A Blood Analyser is an in-vitro diagnostic instrument used to automatically count, classify, test, and flag abnormalities in red blood cells, white blood cells, platelets, hemoglobin, and related hematological parameters from human whole blood samples. It is a core instrument for routine blood testing in hospital laboratories, independent clinical laboratories, health examination centers, and primary healthcare institutions. Typically using impedance, light scattering, fluorescence staining, flow-based detection, and intelligent algorithms, it analyzes cell counts, volume distribution, differential ratios, and abnormal signals. It supports three-part and five-part differentiation, reticulocyte testing, abnormal cell flagging, auto-review rules, and laboratory information system connectivity. Its clinical value lies in delivering fast, stable, and standardized results for infection, anemia, inflammation, bleeding risk, hematological disease screening, and treatment follow-up, making it one of the most widely adopted and clinically relied-upon instruments in modern laboratory medicine.In 2025, global Blood Analyser production reached approximately 111.93 k units and price is about 12.05 k USD/Unit.The average gross profit margin of this product is 45%.

Blood analysers represent one of the most fundamental, high-frequency, and demand-resilient segments within in-vitro diagnostic equipment. Market opportunities are driven by rising healthcare service volume, wider adoption of routine blood testing, laboratory automation upgrades, county-level healthcare capacity building, replacement of installed equipment, and high-end substitution by domestic brands. Complete blood count testing is an entry-level diagnostic item across outpatient, emergency, inpatient, preoperative assessment, infection screening, chronic disease management, oncology follow-up, and health examination scenarios, characterized by high testing frequency, broad patient coverage, and strong clinical dependence. For equipment manufacturers, blood analysers generate not only one-time instrument revenue, but also long-term customer value through reagent matching, quality control, maintenance, software connectivity, and total laboratory solutions, creating a stable installed-base ecosystem.Industry competition has evolved from traditional speed, parameter, and price competition into a broader contest involving accuracy, stability, abnormal sample recognition, anti-interference capability, auto-review rules, after-sales response, and integrated solution capability. High-end healthcare institutions require stronger performance in low platelet detection, abnormal white blood cell flagging, result consistency, automation-line compatibility, and information-system connectivity. Manufacturers must continue investing in core optics, precision fluidics, sensors, algorithms, and quality systems. The primary healthcare market has broad demand but remains price-sensitive, with procurement cycles influenced by budgets, tender policies, and equipment replacement schedules. Imported brands still retain brand inertia among premium customers, while domestic companies need to strengthen competitive barriers through clinical recognition, long-term reliability, and system integration capability.Downstream demand is showing a clear pattern of layered upgrading. Large hospitals focus on high throughput, reduced manual workload, intelligent validation, abnormal sample screening, digital morphology linkage, and laboratory automation connectivity. County hospitals and regional testing centers place greater emphasis on stability, cost-effectiveness, remote quality control, and ease of maintenance. Primary healthcare institutions require accessible instruments that are easy to operate, reliable in results, and low in training cost. Independent clinical laboratories pursue batch-processing efficiency, continuous operation, and optimized unit testing cost. In the future, blood analysers will evolve from standalone routine blood testing tools into key entry points for laboratory digitalization, regional diagnostic collaboration, and clinical data standardization.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Blood Analyser market?

What factors are driving Blood Analyser market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Blood Analyser market opportunities vary by end market size?

How does Blood Analyser break out by Type, by Application?

This report presents a comprehensive overview of the global Blood Analyser market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Three-part Differential
  • Five-part Differential

Segment by System Form

  • Benchtop
  • Floor-standing

Segment by Application

  • Public Hospitals
  • Third-party Independent Laboratory
  • Other

Segment by Application

  • Clinical
  • Screening
  • Research
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Blood Analyser market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Clinical, Screening, Research evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Blood Analyser Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.32B
2025
Forecast
$1.8B
2032
CAGR
4.4%
2025–2032
Regions
5
global
Key companies
Sysmex CorporationDanaherAbbott LaboratoriesSiemens HealthineersHORIBABoule Diagnostics ABNihon KohdenBioSystems
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Three-part DifferentialFive-part Differential
By Application
ClinicalScreeningResearchOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Three-part Differential
  • 3.1.3 Five-part Differential
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Clinical
  • 4.1.3 Screening
  • 4.1.4 Research
  • 4.1.5 Other
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Sysmex Corporation
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Danaher
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Abbott Laboratories
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Siemens Healthineers
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 HORIBA
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Boule Diagnostics AB
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Nihon Kohden
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 BioSystems
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Diatron
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Mindray Medical
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 DYMIND
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Urit Medical
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Zybio
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Dirui Medical
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Maccura
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Sinnowa
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the current global Blood Analyser market size?
The global Blood Analyser market is estimated at US$ 1.32 billion in 2025 (base year) and is projected to reach US$ 1.79 billion by 2032.
What growth rate is expected for the Blood Analyser market through 2032?
The market is expected to grow at a CAGR of 4.4% from 2026 to 2032, expanding from US$ 1.32 billion in 2025 to US$ 1.79 billion in 2032, roughly 1.4 times its base-year value.
How is Blood Analyser defined?
A Blood Analyser is an in-vitro diagnostic instrument used to automatically count, classify, test, and flag abnormalities in red blood cells, white blood cells, platelets, hemoglobin, and related hematological parameters from human whole blood samples. It is a core instrument for routine blood testing in hospital laboratories, independent clinical laboratories, health examination centers, and primary healthcare institutions.
How is the Blood Analyser market segmented by type?
By type, the market is segmented into Three-part Differential and Five-part Differential.
What are the key applications of Blood Analyser?
Key applications covered include Clinical, Screening, Research and Other.
Which companies are profiled in the Blood Analyser market report?
Key players profiled include Sysmex Corporation, Danaher, Abbott Laboratories, Siemens Healthineers, HORIBA, Boule Diagnostics AB, Nihon Kohden and BioSystems, among 16 companies covered in total.
What geographies does the Blood Analyser market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Blood Analyser?
Market opportunities are driven by rising healthcare service volume, wider adoption of routine blood testing, laboratory automation upgrades, county-level healthcare capacity building, replacement of installed equipment, and high-end substitution by domestic brands.
What are the main risks and barriers in the Blood Analyser market?
Imported brands still retain brand inertia among premium customers, while domestic companies need to strengthen competitive barriers through clinical recognition, long-term reliability, and system integration capability.Downstream demand is showing a clear pattern of layered upgrading.
Who should buy the Blood Analyser market report?
The report is intended for manufacturers and solution providers, distributors and end users in Clinical, Screening and Research, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Blood Analyser market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from ‏3,500.00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.